首页 > 最新文献

Allergy最新文献

英文 中文
Polyethylene Terephthalate Micro and Nanoplastics Induce Oxidative and Endoplasmic Reticulum Stress, Compromising Intestinal Epithelial Integrity and Viability 聚对苯二甲酸乙二醇酯微塑料和纳米塑料诱导氧化和内质网应激,损害肠上皮的完整性和活力
IF 12.4 1区 医学 Q1 ALLERGY Pub Date : 2026-03-26 DOI: 10.1111/all.70291
Sena Ardicli, Huseyn Babayev, Lihong Chang, Ozge Ardicli, Can Zeyneloglu, Yagiz Pat, Duygu Yazici, Xiaoqing Liu, Ezgi Irem Bektas, Carina Beha, Halil I. Akyildiz, Nazrin B. Mammadova, Muhammed Emin Sari, Beate Rückert, Raja Dhir, Ismail Ogulur, Kari C. Nadeau, Mubeccel Akdis, Cezmi A. Akdis
{"title":"Polyethylene Terephthalate Micro and Nanoplastics Induce Oxidative and Endoplasmic Reticulum Stress, Compromising Intestinal Epithelial Integrity and Viability","authors":"Sena Ardicli, Huseyn Babayev, Lihong Chang, Ozge Ardicli, Can Zeyneloglu, Yagiz Pat, Duygu Yazici, Xiaoqing Liu, Ezgi Irem Bektas, Carina Beha, Halil I. Akyildiz, Nazrin B. Mammadova, Muhammed Emin Sari, Beate Rückert, Raja Dhir, Ismail Ogulur, Kari C. Nadeau, Mubeccel Akdis, Cezmi A. Akdis","doi":"10.1111/all.70291","DOIUrl":"https://doi.org/10.1111/all.70291","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"9 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2026-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147507911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Malassezia ‐Induced Type 2 Immunity in Head Neck Shoulder Type Atopic Dermatitis 马拉色菌诱导的头颈肩型特应性皮炎的2型免疫
IF 12.4 1区 医学 Q1 ALLERGY Pub Date : 2026-03-25 DOI: 10.1111/all.70302
I. Suhrkamp, T. Heidland, C. Saft, A. K. Kamps, S. Edenhart, O. Kniemeyer, W. Francuzik, S. Weidinger, P. Bacher, C. Bang, G. Heine
{"title":"Malassezia ‐Induced Type 2 Immunity in Head Neck Shoulder Type Atopic Dermatitis","authors":"I. Suhrkamp, T. Heidland, C. Saft, A. K. Kamps, S. Edenhart, O. Kniemeyer, W. Francuzik, S. Weidinger, P. Bacher, C. Bang, G. Heine","doi":"10.1111/all.70302","DOIUrl":"https://doi.org/10.1111/all.70302","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"235 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2026-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147506681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Early‐Life Viral Infections as Architects of Asthma Susceptibility 早期生命病毒感染是哮喘易感性的建筑师
IF 12.4 1区 医学 Q1 ALLERGY Pub Date : 2026-03-25 DOI: 10.1111/all.70315
Dominika Ambrożej, Karolina Dumycz, Wojciech Feleszko
{"title":"Early‐Life Viral Infections as Architects of Asthma Susceptibility","authors":"Dominika Ambrożej, Karolina Dumycz, Wojciech Feleszko","doi":"10.1111/all.70315","DOIUrl":"https://doi.org/10.1111/all.70315","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"9 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2026-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147506679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IL ‐33 Drives Inflammatory Changes and Extracellular Trap Formation in Eosinophils Involving Oxidised LDL and Complement Pathways IL - 33驱动嗜酸性粒细胞炎症变化和细胞外陷阱形成,涉及氧化LDL和补体途径
IF 12.4 1区 医学 Q1 ALLERGY Pub Date : 2026-03-25 DOI: 10.1111/all.70313
Emiko Matsuyama, Jun Miyata, Takao Mochimaru, Ryuta Onozato, Yo Otsu, Hisashi Sasaki, Keeya Sunata, Shinichi Okuzumi, Katsunori Masaki, Hiroki Kabata, Keinosuke Hizuka, Yoshinori Hasegawa, Ryo Konno, Yusuke Kawashima, Makoto Arita, Shigeharu Ueki, Koichi Fukunaga
Background IL‐33 levels are elevated in the airways of patients with eosinophilic diseases, and IL‐33 receptor expression on eosinophils is upregulated in type 2‐high environments. However, the role of IL‐33 in the regulation of human eosinophils remains unclear. Objective To elucidate the inflammatory effects of IL‐33 on the cellular function of human eosinophils. Methods Blood eosinophils were stimulated with IL‐33, TNF‐α, oxidised low‐density lipoprotein (oxLDL) and complement fragments (C3a and C5a). Multi‐omics analyses, including transcriptomics and proteomics, were performed. Extracellular trap formation (ETosis) was assessed by SYTOX nucleic acid staining and was visualised by immunofluorescence and transmission electron microscopy. Results Multi‐omics analyses revealed an IL‐33‐ and TNF‐α‐induced inflammatory gene signature characterised by the upregulation of cell surface markers (oxLDL receptor 1, CD22, CD4 and ICAM‐1) and inflammatory mediators (C3, CCL3/4 and IL1A/B). CD22 upregulation was specific to IL‐33 stimulation. Eosinophils derived from nasal polyps exhibited a gene expression profile similar to that of IL‐33‐stimulated eosinophils. Functional assays demonstrated that oxLDL and complement fragments differentially prolonged eosinophil survival and altered the expression of adhesion molecules. OxLDL‐ and complement fragment‐induced gene signatures were partly detected in eosinophils derived from nasal polyps. Furthermore, IL‐33 triggered ETosis via NADPH oxidase, mitogen‐activated protein kinase and phosphoinositide 3‐kinase pathways. Conclusions IL‐33, in conjunction with oxLDL and the complement cascade, induces inflammatory changes in eosinophils, promoting an ETosis‐prone phenotype. These pathways represent potential therapeutic targets in refractory eosinophilic diseases.
背景:嗜酸性粒细胞疾病患者气道中IL - 33水平升高,2型高环境下嗜酸性粒细胞IL - 33受体表达上调。然而,IL - 33在调节人类嗜酸性粒细胞中的作用尚不清楚。目的探讨IL - 33对人嗜酸性粒细胞细胞功能的影响。方法用IL - 33、TNF - α、氧化低密度脂蛋白(oxLDL)和补体片段(C3a和C5a)刺激血液嗜酸性粒细胞。进行多组学分析,包括转录组学和蛋白质组学。细胞外陷阱形成(ETosis)采用SYTOX核酸染色评估,免疫荧光和透射电镜观察。结果多组学分析显示,IL - 33和TNF - α诱导的炎症基因特征以细胞表面标记物(oxLDL受体1、CD22、CD4和ICAM - 1)和炎症介质(C3、CCL3/4和IL1A/B)的上调为特征。CD22的上调是IL - 33刺激所特有的。来自鼻息肉的嗜酸性粒细胞表现出与IL - 33刺激的嗜酸性粒细胞相似的基因表达谱。功能分析表明,oxLDL和补体片段延长了嗜酸性粒细胞的存活时间,并改变了粘附分子的表达。在鼻息肉衍生的嗜酸性粒细胞中部分检测到OxLDL -和补体片段诱导的基因特征。此外,IL - 33通过NADPH氧化酶、有丝分裂原活化蛋白激酶和磷酸肌肽3激酶途径触发ETosis。IL - 33,与oxLDL和补体级联结合,诱导嗜酸性粒细胞的炎症变化,促进ETosis易感性表型。这些途径代表了难治性嗜酸性粒细胞疾病的潜在治疗靶点。
{"title":"IL ‐33 Drives Inflammatory Changes and Extracellular Trap Formation in Eosinophils Involving Oxidised LDL and Complement Pathways","authors":"Emiko Matsuyama, Jun Miyata, Takao Mochimaru, Ryuta Onozato, Yo Otsu, Hisashi Sasaki, Keeya Sunata, Shinichi Okuzumi, Katsunori Masaki, Hiroki Kabata, Keinosuke Hizuka, Yoshinori Hasegawa, Ryo Konno, Yusuke Kawashima, Makoto Arita, Shigeharu Ueki, Koichi Fukunaga","doi":"10.1111/all.70313","DOIUrl":"https://doi.org/10.1111/all.70313","url":null,"abstract":"Background IL‐33 levels are elevated in the airways of patients with eosinophilic diseases, and IL‐33 receptor expression on eosinophils is upregulated in type 2‐high environments. However, the role of IL‐33 in the regulation of human eosinophils remains unclear. Objective To elucidate the inflammatory effects of IL‐33 on the cellular function of human eosinophils. Methods Blood eosinophils were stimulated with IL‐33, TNF‐α, oxidised low‐density lipoprotein (oxLDL) and complement fragments (C3a and C5a). Multi‐omics analyses, including transcriptomics and proteomics, were performed. Extracellular trap formation (ETosis) was assessed by SYTOX nucleic acid staining and was visualised by immunofluorescence and transmission electron microscopy. Results Multi‐omics analyses revealed an IL‐33‐ and TNF‐α‐induced inflammatory gene signature characterised by the upregulation of cell surface markers (oxLDL receptor 1, CD22, CD4 and ICAM‐1) and inflammatory mediators (C3, CCL3/4 and IL1A/B). CD22 upregulation was specific to IL‐33 stimulation. Eosinophils derived from nasal polyps exhibited a gene expression profile similar to that of IL‐33‐stimulated eosinophils. Functional assays demonstrated that oxLDL and complement fragments differentially prolonged eosinophil survival and altered the expression of adhesion molecules. OxLDL‐ and complement fragment‐induced gene signatures were partly detected in eosinophils derived from nasal polyps. Furthermore, IL‐33 triggered ETosis via NADPH oxidase, mitogen‐activated protein kinase and phosphoinositide 3‐kinase pathways. Conclusions IL‐33, in conjunction with oxLDL and the complement cascade, induces inflammatory changes in eosinophils, promoting an ETosis‐prone phenotype. These pathways represent potential therapeutic targets in refractory eosinophilic diseases.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"33 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2026-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147506680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Allergic Rhinitis and Its Impact on Asthma ( ARIA )‐ EAACI Guidelines—2024–2025 Revision: Part II —Guidelines on Oral and Ocular Treatments 变应性鼻炎及其对哮喘的影响(ARIA) - EAACI指南- 2024 - 2025修订:第二部分-口腔和眼部治疗指南
IF 12.4 1区 医学 Q1 ALLERGY Pub Date : 2026-03-25 DOI: 10.1111/all.70305
Rafael José Vieira, Bernardo Sousa‐Pinto, Jean Bousquet, Holger J. Schünemann, Torsten Zuberbier, Antonio Bognanni, Alkis Togias, Boleslaw Samolinski, Arunas Valiulis, Sian Williams, Anna Bedbrook, Wienczyslawa Czarlewski, Maria Jose Torres, Mohamed H. Shamji, Mário Morais‐Almeida, G. Walter Canonica, Leticia de las Vecillas, Mark S. Dykewicz, Cristina Jacomelli, Ludger Klimek, Lucas Leemann, Olga Lourenço, Nikolaos G. Papadopoulos, Ana Margarida Pereira, Marine Savouré, Sanna K. Toppila‐Salmi, Maria Teresa Ventura, Juan José Yepes‐Nuñez, Alvaro A. Cruz, Giorgio Ciprandi, Bilun Gemicioglu, Mattia Giovannini, Brigita Gradauskiene, Tuomas Jartti, Miloš Jeseňák, Piotr Kuna, Violeta Kvedariene, Désirée E. Larenas‐Linnemann, Amir H. A. Latiff, Yousser Mohammad, Ken Ohta, Padukudru A. Mahesh, Isabella Pali‐Schöll, Oliver Pfaar, Frederico S. Regateiro, Nicolas Roche, Luís Taborda‐Barata, Charlotte Suppli Ulrik, Giovanni Viegi, Luo Zhang, Tari Haahtela, Ivan Cherrez‐Ojeda, Juan Carlos Ivancevich, Nikolai Khaltaev, Arzu Yorgancioglu, Baharudin Abdullah, Mona Al‐Ahmad, Maryam Ali Al‐Nesf, Rita Amaral, Julijana Asllani, Karl‐C. Bergmann, Jonathan A. Bernstein, Michael S. Blaiss, Elina Toskala, Pedro Carreiro‐Martins, Thomas Casale, Lorenzo Cecchi, Alessandro Fiocchi, Antonio F. M. Giuliano, George Christoff, Ieva Cirule, Jaime Correia de Sousa, Elisio M. Costa, Philippe Devillier, Elham Hossny, Tomohisa Iinuma, Zhanat Ispayeva, Kaja Julge, Igor Kaidashev, Kazi S. Bennoor, Helga Kraxner, Inger Kull, Marek Kulus, Maciej Kupczyk, Andriy Kurchenko, Stefania La Grutta, Neven Miculinic, Lan Le Thi Tuyet, Sang Min Lee, Stephen Montefort, Andre Moreira, Joaquim Mullol, Rachel Nadif, Alla Nakonechna, Hugo E. Neffen, Marek Niedoszytko, Robyn E. O'Hehir, Ismail Ogulur, Yoshitaka Okamoto, Heidi Olze, Oscar Palomares, Petr Panzner, Vincenzo Patella, Constantinos Pitsios, Francesca Puggioni, Santiago Quirce, Agné Ramonaité, Maria Susana Repka‐Ramirez, Graham Roberts, Karla Robles‐Velasco, Menachem Rottem, Marianella Salapatas, Joaquin Sastre, Nicola Scichilone, Juan‐Carlos Sisul, Dirceu Solé, Manuel E. Soto‐Martinez, Milan Sova, Pongsakorn Tantilipikorn, Ana Todo‐Bom, Vladyslav Tsaryk, Ioanna Tsiligianni, Marilyn Urrutia‐Pereira, Erkka Valovirta, Tuula Vasankari, Dana Wallace, De Yun Wang, Margitta Worm, Osman M. Yusuf, Sara Gil‐Mata, Manuel Marques‐Cruz, Bassam Mahboub, Antonino Romano, Werner Aberer, Maria Cristina Artesani, Elena Azzolini, Bruno Barreto, Joan Bartra, Sven Becker, Bianca Beghe, Attilio Boner, Ewa Borowiack, Jacques Bouchard, Luisa Brussino, Roland Buhl, Francesco Catamerò, Denis Charpin, Niels H. Chavannes, Marta Chełmińska, Lei Cheng, Ekaterine Chkhartishvili, Seong H. Cho, Herberto Jose Chong‐Neto, Derek K. Chu, Cemal Cingi, Enrico Compalati, Raquel Albuquerque Costa, Biljana Cvetkovski, Victoria Cardona, Gennaro D'Amato, Janet M. Davies, Danilo Di Bona, Sandra N. Gonzalez Diaz, Maria V. Dimou, Maria Doulaptsi, Renato Ferreira‐da‐Silva, Radoslaw Gawlik, Mario Calvo‐Gil, Maximiliano R. Gómez, Maia Gotua, Christos Grigoreas, Maria Antonieta Guzman, Rachel House, Michael Hyland, Despo Ierodiakonou, Aspasia Karavelia, Paul Keith, Marta Kisiel, Tanja Soklic Kosak, Mitja Kosnik, Ilgim Vardaloglu Koyuncu, Vicky Kritikos, Justyna Litynska, Carlo Lombardi, Gilles Louis, Xin Luo, Matteo Martini, Cem Meço, Eris Mesonjesi, Florin Mihaltan, Marcin Moniuszko, Robert N. Naclerio, Sophia Neisinger, Markus Ollert, Michal Ordak, Giovanni Paoletti, Elena Parmelli, Edgar Arturo Perdomo‐Flores, Henrique Pereira, José Miguel Fuentes Pérez, Nhan Pham‐Thi, Emmanuel Prokopakis, Inês Ribeiro‐Vaz, Giovanni Rolla, Jan Romantowski, Philippe Rombaux, Philip W. Rouadi, Dermot Ryan, Ewelina Sadowska, Daiju Sakurai, Laila Salameh, Elie Serrano, Jane Da Silva, Michael B. Soyka, Krzysztof Specjalski, Vesna Tomic‐Spiric, Katarina Stevanovic, Abirami Subramaniam, Tuuli Thomander, Wu Tong, Martina Vachova, Marianne van Hage, Martin Wagenmann, Fanny Wai San Ko, Pascal Werminghaus, Paraskevi Vicky Xepapadaki, Yi‐Kui Xiang, Qintai Yang, He Zhang, Jaron Zuberbier, João A. Fonseca
Background Oral and ocular medications are frequently used in the treatment of allergic rhinitis (AR). As part of the update of the Allergic Rhinitis and its Impact on Asthma (ARIA)‐EAACI guidelines, this manuscript presents the ARIA‐EAACI 2024–2025 recommendations for oral and ocular treatments. Methods The ARIA‐EAACI 2024–2025 guideline panel issued recommendations following the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) evidence‐to‐decision framework. Several sources of evidence were used to inform panel judgements and recommendations, including systematic reviews, mHealth and pharmacovigilance data as well as a survey on costs. Results Eight guideline questions concerning oral treatments for AR and three questions concerning ocular treatments were addressed. These questions led to the recommendations. Overall, these questions concern the choice between different classes of medication. They also discuss the role of oral antihistamines (OAH), leukotriene receptor antagonists (LTRA), ocular antihistamines (OcAH) and ocular mast cell stabilisers. Four questions had not been previously evaluated in ARIA guidelines, while, for the other four, there was a change in the strength or directionality of the recommendations. Overall, these guidelines recommend using intranasal corticosteroids over OAH and using OAH over LTRA. Moreover, they suggest using OAH over OcAH and suggest being against adding LTRA to OAH. Finally, considerations for choosing between different individual OAHs are presented. Conclusion This ARIA‐EAACI 2024–2025 article supports patients, their caregivers and healthcare professionals in choosing oral and ocular treatments for AR. Decisions on treatment should consider the clinical variability of the disease, patients' values and the affordability of medications.
背景:在变应性鼻炎(AR)的治疗中,经常使用口服和眼部药物。作为变应性鼻炎及其对哮喘的影响(ARIA) - EAACI指南更新的一部分,本文提出了ARIA - EAACI 2024-2025口腔和眼部治疗建议。方法ARIA - EAACI 2024-2025指南小组根据推荐、评估、发展和评价(GRADE)证据-决策框架的分级发布建议。专家组的判断和建议采用了若干证据来源,包括系统审查、移动健康和药物警戒数据以及成本调查。结果回答了AR口腔治疗的8个指南问题和眼部治疗的3个指南问题。这些问题导致了这些建议。总的来说,这些问题涉及不同类别药物的选择。他们还讨论了口服抗组胺药(OAH)、白三烯受体拮抗剂(LTRA)、眼抗组胺药(OcAH)和眼肥大细胞稳定剂的作用。有四个问题以前没有在ARIA指南中进行评估,而对于其他四个问题,建议的力度或方向发生了变化。总的来说,这些指南建议使用鼻内皮质类固醇而不是OAH,使用OAH而不是LTRA。此外,他们建议使用OAH而不是OcAH,并建议不要在OAH中添加LTRA。最后,提出了在不同个体OAHs之间进行选择的注意事项。结论:ARIA‐EAACI 2024-2025这篇文章支持AR患者、他们的护理人员和医疗保健专业人员选择口腔和眼部治疗方法。治疗决策应考虑疾病的临床变异性、患者的价值观和药物的可承受性。
{"title":"Allergic Rhinitis and Its Impact on Asthma ( ARIA )‐ EAACI Guidelines—2024–2025 Revision: Part II —Guidelines on Oral and Ocular Treatments","authors":"Rafael José Vieira, Bernardo Sousa‐Pinto, Jean Bousquet, Holger J. Schünemann, Torsten Zuberbier, Antonio Bognanni, Alkis Togias, Boleslaw Samolinski, Arunas Valiulis, Sian Williams, Anna Bedbrook, Wienczyslawa Czarlewski, Maria Jose Torres, Mohamed H. Shamji, Mário Morais‐Almeida, G. Walter Canonica, Leticia de las Vecillas, Mark S. Dykewicz, Cristina Jacomelli, Ludger Klimek, Lucas Leemann, Olga Lourenço, Nikolaos G. Papadopoulos, Ana Margarida Pereira, Marine Savouré, Sanna K. Toppila‐Salmi, Maria Teresa Ventura, Juan José Yepes‐Nuñez, Alvaro A. Cruz, Giorgio Ciprandi, Bilun Gemicioglu, Mattia Giovannini, Brigita Gradauskiene, Tuomas Jartti, Miloš Jeseňák, Piotr Kuna, Violeta Kvedariene, Désirée E. Larenas‐Linnemann, Amir H. A. Latiff, Yousser Mohammad, Ken Ohta, Padukudru A. Mahesh, Isabella Pali‐Schöll, Oliver Pfaar, Frederico S. Regateiro, Nicolas Roche, Luís Taborda‐Barata, Charlotte Suppli Ulrik, Giovanni Viegi, Luo Zhang, Tari Haahtela, Ivan Cherrez‐Ojeda, Juan Carlos Ivancevich, Nikolai Khaltaev, Arzu Yorgancioglu, Baharudin Abdullah, Mona Al‐Ahmad, Maryam Ali Al‐Nesf, Rita Amaral, Julijana Asllani, Karl‐C. Bergmann, Jonathan A. Bernstein, Michael S. Blaiss, Elina Toskala, Pedro Carreiro‐Martins, Thomas Casale, Lorenzo Cecchi, Alessandro Fiocchi, Antonio F. M. Giuliano, George Christoff, Ieva Cirule, Jaime Correia de Sousa, Elisio M. Costa, Philippe Devillier, Elham Hossny, Tomohisa Iinuma, Zhanat Ispayeva, Kaja Julge, Igor Kaidashev, Kazi S. Bennoor, Helga Kraxner, Inger Kull, Marek Kulus, Maciej Kupczyk, Andriy Kurchenko, Stefania La Grutta, Neven Miculinic, Lan Le Thi Tuyet, Sang Min Lee, Stephen Montefort, Andre Moreira, Joaquim Mullol, Rachel Nadif, Alla Nakonechna, Hugo E. Neffen, Marek Niedoszytko, Robyn E. O'Hehir, Ismail Ogulur, Yoshitaka Okamoto, Heidi Olze, Oscar Palomares, Petr Panzner, Vincenzo Patella, Constantinos Pitsios, Francesca Puggioni, Santiago Quirce, Agné Ramonaité, Maria Susana Repka‐Ramirez, Graham Roberts, Karla Robles‐Velasco, Menachem Rottem, Marianella Salapatas, Joaquin Sastre, Nicola Scichilone, Juan‐Carlos Sisul, Dirceu Solé, Manuel E. Soto‐Martinez, Milan Sova, Pongsakorn Tantilipikorn, Ana Todo‐Bom, Vladyslav Tsaryk, Ioanna Tsiligianni, Marilyn Urrutia‐Pereira, Erkka Valovirta, Tuula Vasankari, Dana Wallace, De Yun Wang, Margitta Worm, Osman M. Yusuf, Sara Gil‐Mata, Manuel Marques‐Cruz, Bassam Mahboub, Antonino Romano, Werner Aberer, Maria Cristina Artesani, Elena Azzolini, Bruno Barreto, Joan Bartra, Sven Becker, Bianca Beghe, Attilio Boner, Ewa Borowiack, Jacques Bouchard, Luisa Brussino, Roland Buhl, Francesco Catamerò, Denis Charpin, Niels H. Chavannes, Marta Chełmińska, Lei Cheng, Ekaterine Chkhartishvili, Seong H. Cho, Herberto Jose Chong‐Neto, Derek K. Chu, Cemal Cingi, Enrico Compalati, Raquel Albuquerque Costa, Biljana Cvetkovski, Victoria Cardona, Gennaro D'Amato, Janet M. Davies, Danilo Di Bona, Sandra N. Gonzalez Diaz, Maria V. Dimou, Maria Doulaptsi, Renato Ferreira‐da‐Silva, Radoslaw Gawlik, Mario Calvo‐Gil, Maximiliano R. Gómez, Maia Gotua, Christos Grigoreas, Maria Antonieta Guzman, Rachel House, Michael Hyland, Despo Ierodiakonou, Aspasia Karavelia, Paul Keith, Marta Kisiel, Tanja Soklic Kosak, Mitja Kosnik, Ilgim Vardaloglu Koyuncu, Vicky Kritikos, Justyna Litynska, Carlo Lombardi, Gilles Louis, Xin Luo, Matteo Martini, Cem Meço, Eris Mesonjesi, Florin Mihaltan, Marcin Moniuszko, Robert N. Naclerio, Sophia Neisinger, Markus Ollert, Michal Ordak, Giovanni Paoletti, Elena Parmelli, Edgar Arturo Perdomo‐Flores, Henrique Pereira, José Miguel Fuentes Pérez, Nhan Pham‐Thi, Emmanuel Prokopakis, Inês Ribeiro‐Vaz, Giovanni Rolla, Jan Romantowski, Philippe Rombaux, Philip W. Rouadi, Dermot Ryan, Ewelina Sadowska, Daiju Sakurai, Laila Salameh, Elie Serrano, Jane Da Silva, Michael B. Soyka, Krzysztof Specjalski, Vesna Tomic‐Spiric, Katarina Stevanovic, Abirami Subramaniam, Tuuli Thomander, Wu Tong, Martina Vachova, Marianne van Hage, Martin Wagenmann, Fanny Wai San Ko, Pascal Werminghaus, Paraskevi Vicky Xepapadaki, Yi‐Kui Xiang, Qintai Yang, He Zhang, Jaron Zuberbier, João A. Fonseca","doi":"10.1111/all.70305","DOIUrl":"https://doi.org/10.1111/all.70305","url":null,"abstract":"Background Oral and ocular medications are frequently used in the treatment of allergic rhinitis (AR). As part of the update of the Allergic Rhinitis and its Impact on Asthma (ARIA)‐EAACI guidelines, this manuscript presents the ARIA‐EAACI 2024–2025 recommendations for oral and ocular treatments. Methods The ARIA‐EAACI 2024–2025 guideline panel issued recommendations following the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) evidence‐to‐decision framework. Several sources of evidence were used to inform panel judgements and recommendations, including systematic reviews, mHealth and pharmacovigilance data as well as a survey on costs. Results Eight guideline questions concerning oral treatments for AR and three questions concerning ocular treatments were addressed. These questions led to the recommendations. Overall, these questions concern the choice between different classes of medication. They also discuss the role of oral antihistamines (OAH), leukotriene receptor antagonists (LTRA), ocular antihistamines (OcAH) and ocular mast cell stabilisers. Four questions had not been previously evaluated in ARIA guidelines, while, for the other four, there was a change in the strength or directionality of the recommendations. Overall, these guidelines recommend using intranasal corticosteroids over OAH and using OAH over LTRA. Moreover, they suggest using OAH over OcAH and suggest being against adding LTRA to OAH. Finally, considerations for choosing between different individual OAHs are presented. Conclusion This ARIA‐EAACI 2024–2025 article supports patients, their caregivers and healthcare professionals in choosing oral and ocular treatments for AR. Decisions on treatment should consider the clinical variability of the disease, patients' values and the affordability of medications.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"35 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2026-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147506678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to "Epicutaneous Sensitization in the Development of Food Allergy: What Is the Evidence and How Can This be Prevented?" 更正“食物过敏发展过程中的表皮致敏:证据是什么以及如何预防?”
IF 12.4 1区 医学 Q1 ALLERGY Pub Date : 2026-03-24 DOI: 10.1111/all.70320
{"title":"Correction to \"Epicutaneous Sensitization in the Development of Food Allergy: What Is the Evidence and How Can This be Prevented?\"","authors":"","doi":"10.1111/all.70320","DOIUrl":"https://doi.org/10.1111/all.70320","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"19 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2026-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147502357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence of Type 2 Inflammation in Chronic Obstructive Pulmonary Disease Patients With Frequent Exacerbations. 慢性阻塞性肺疾病频繁发作患者2型炎症的患病率
IF 12.4 1区 医学 Q1 ALLERGY Pub Date : 2026-03-24 DOI: 10.1111/all.70300
Mireille C Melles,Johannes C C M In 't Veen,Dirk-Jan Slebos,Frits M E Franssen,Marlies van Dijk,Pieter-Paul W Hekking
{"title":"Prevalence of Type 2 Inflammation in Chronic Obstructive Pulmonary Disease Patients With Frequent Exacerbations.","authors":"Mireille C Melles,Johannes C C M In 't Veen,Dirk-Jan Slebos,Frits M E Franssen,Marlies van Dijk,Pieter-Paul W Hekking","doi":"10.1111/all.70300","DOIUrl":"https://doi.org/10.1111/all.70300","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"17 2 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2026-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147502359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Increased Primary Cilia Contribute to Airway Epithelium Remodeling in Asthma. 原发性纤毛增加有助于哮喘气道上皮重塑。
IF 12.4 1区 医学 Q1 ALLERGY Pub Date : 2026-03-23 DOI: 10.1111/all.70309
Gongqi Chen,Huiru Jie,Chunli Huang,Zhen Wang,Wei Gu,Tiantian Xiong,Yanxin Liu,Yuchen Feng,Lingling Yi,Zheng Xue,Guohua Zhen
{"title":"Increased Primary Cilia Contribute to Airway Epithelium Remodeling in Asthma.","authors":"Gongqi Chen,Huiru Jie,Chunli Huang,Zhen Wang,Wei Gu,Tiantian Xiong,Yanxin Liu,Yuchen Feng,Lingling Yi,Zheng Xue,Guohua Zhen","doi":"10.1111/all.70309","DOIUrl":"https://doi.org/10.1111/all.70309","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"92 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2026-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147502394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chinese Position Paper on Biologic Therapy for Allergic Rhinitis. 变应性鼻炎生物治疗中国立场文件。
IF 12.4 1区 医学 Q1 ALLERGY Pub Date : 2026-03-23 DOI: 10.1111/all.70312
Yuan Zhang,Jingyun Li,Xian Li,Menglin Wang,Xiangli Yang,Li Shi,Zhiwei Cao,Yan Feng,Weiwei Liu,Zhendong Xu,Ruixia Ma,Xiaoping Gao,Wen Liu,Jinmei Xue,Xiaoyong Ren,Xuezhong Li,Xicheng Song,Yi Yang,Fang Quan,Lei Cheng,Weihong Jiang,Huabin Li,Jian Li,Huanhai Liu,Jianfeng Liu,Zheng Liu,Wei Lv,Qianhui Qiu,Xiangdong Wang,Yu Xu,Yuanteng Xu,Qintai Yang,Yucheng Yang,Jing Ye,Hongmeng Yu,Dongdong Zhu,Chengshuo Wang,Luo Zhang
Allergic rhinitis (AR) is a common, persistent nasal disorder that poses significant public health challenges worldwide. Current treatment options frequently fail to achieve adequate symptom control in a substantial subset of patients. Over the past two decades, biologic therapies that target type 2 inflammatory pathways have been used to treat patients experiencing poorly controlled symptoms, despite standard-of-care (SoC) treatment. Although biological treatment options for AR remain limited worldwide, the recent approval of novel agents, such as stapokibart for seasonal allergic rhinitis (SAR), has accelerated clinical research and development in this field. Evidence for biologic therapy in the management of perennial allergic rhinitis (PAR) is currently sparse. To standardise the use of biologics in AR management and promote their evidence-based application, a multidisciplinary expert panel was convened. This position paper evaluates current evidence regarding the efficacy and safety of biologic agents for AR, incorporating data from both international and regional clinical studies. Here, we provide recommendations on appropriate indications for biologic therapy and emphasise its role in patients with uncontrolled SAR, supporting clinical decision-making and facilitating the integration of biologics into routine practice.
过敏性鼻炎(AR)是一种常见的持续性鼻部疾病,在全球范围内构成了重大的公共卫生挑战。目前的治疗方案往往不能实现充分的症状控制在一个相当大的子集的患者。在过去的二十年中,尽管有标准治疗(SoC)治疗,但针对2型炎症途径的生物疗法已被用于治疗症状控制不佳的患者。尽管AR的生物治疗方案在世界范围内仍然有限,但最近批准的新药物,如用于季节性变应性鼻炎(SAR)的stapokibart,加速了该领域的临床研究和开发。生物疗法治疗常年性变应性鼻炎(PAR)的证据目前很少。为了规范AR管理中生物制剂的使用并促进其循证应用,召开了一个多学科专家小组会议。本文结合国际和地区临床研究的数据,评估了目前关于生物制剂治疗AR的有效性和安全性的证据。在这里,我们提供了适当的生物治疗适应症的建议,并强调其在不受控制的SAR患者中的作用,支持临床决策并促进生物制剂融入常规实践。
{"title":"Chinese Position Paper on Biologic Therapy for Allergic Rhinitis.","authors":"Yuan Zhang,Jingyun Li,Xian Li,Menglin Wang,Xiangli Yang,Li Shi,Zhiwei Cao,Yan Feng,Weiwei Liu,Zhendong Xu,Ruixia Ma,Xiaoping Gao,Wen Liu,Jinmei Xue,Xiaoyong Ren,Xuezhong Li,Xicheng Song,Yi Yang,Fang Quan,Lei Cheng,Weihong Jiang,Huabin Li,Jian Li,Huanhai Liu,Jianfeng Liu,Zheng Liu,Wei Lv,Qianhui Qiu,Xiangdong Wang,Yu Xu,Yuanteng Xu,Qintai Yang,Yucheng Yang,Jing Ye,Hongmeng Yu,Dongdong Zhu,Chengshuo Wang,Luo Zhang","doi":"10.1111/all.70312","DOIUrl":"https://doi.org/10.1111/all.70312","url":null,"abstract":"Allergic rhinitis (AR) is a common, persistent nasal disorder that poses significant public health challenges worldwide. Current treatment options frequently fail to achieve adequate symptom control in a substantial subset of patients. Over the past two decades, biologic therapies that target type 2 inflammatory pathways have been used to treat patients experiencing poorly controlled symptoms, despite standard-of-care (SoC) treatment. Although biological treatment options for AR remain limited worldwide, the recent approval of novel agents, such as stapokibart for seasonal allergic rhinitis (SAR), has accelerated clinical research and development in this field. Evidence for biologic therapy in the management of perennial allergic rhinitis (PAR) is currently sparse. To standardise the use of biologics in AR management and promote their evidence-based application, a multidisciplinary expert panel was convened. This position paper evaluates current evidence regarding the efficacy and safety of biologic agents for AR, incorporating data from both international and regional clinical studies. Here, we provide recommendations on appropriate indications for biologic therapy and emphasise its role in patients with uncontrolled SAR, supporting clinical decision-making and facilitating the integration of biologics into routine practice.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"17 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2026-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147502393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Frequency and Severity of Allergic Reactions to Non-Mandatory Labelled Allergenic Foods-Data From Two Large European Cohorts. 对非强制性标签致敏性食品过敏反应的频率和严重程度——来自两个大型欧洲队列的数据。
IF 12.4 1区 医学 Q1 ALLERGY Pub Date : 2026-03-23 DOI: 10.1111/all.70308
Sabine Dölle-Bierke,Alejandro Gonzalo-Fernández,Dominique Sabouraud-Leclerc,Laura Barreales-Tolosa,Barbara Ballmer-Weber,Simona Belohlavkova,Maria B Bilò,Ruta Dubakiene,Karin Hartmann,Monika Jedrzejczak-Czechowicz,Thuy-My Le,Lars Lange,Nikolaos G Papadopoulos,Guillaume Pouessel,Isabel Reig,Athanasios Sinaniotis,E N Clare Mills,Margitta Worm,Montserrat Fernández-Rivas
BACKGROUNDThe consumption of plant-based food has lately largely increased, raising concerns about allergic reactions from ingredients which are currently not subject to mandatory labelling.METHODSWe analysed the frequency and severity of allergic reactions to non-mandatory labelled allergenic foods (pea, lentil, bean, chickpea, fenugreek, pine nut, sunflower-, poppy-, pumpkin seed, buckwheat) from two large European cohorts: The Anaphylaxis Registry (NORA) and EuroPrevall outpatient clinic study. Severity was assessed using the Food Allergy Severity Score (FASS) and compared with reactions to mandatory labelled allergenic foods.RESULTSAmong 589 reactions from both cohorts, sunflower seed was the most frequent trigger (n = 126). In NORA, pine nut (1.0% of food-induced allergic reactions) was most common followed by pea and buckwheat (0.7% each); in EuroPrevall, sunflower seed (1.2%), poppy seed (0.6%) and lentil (0.6%) predominated. After adjusting for age and sex, the severity of reactions to mandatory labelled seeds and legumes (excluding peanut) were not different (nFASS median: 4.39 vs. 4.43 and 4.56 vs. 4.49). Whereas, cereal-induced reactions (6.47) were significantly more severe than buckwheat (4.77). In Nora, the number of reactions to fenugreek and pumpkin seed were 7.4- and 3.7-fold higher in 2015-2022 versus 2007-2014.CONCLUSIONNon-mandatory labelled allergenic foods were identified to cause severe allergic reactions in two large European cohorts. The frequent involvement of sunflower seed, pine nut, pea and lentil, but also rising numbers of reactions to fenugreek and pumpkin seed, indicates their potential risk. These allergenic foods warrant close monitoring and consideration in future allergen labelling revisions.
植物性食品的消费量最近大幅增加,引起了人们对目前没有强制性标签的成分的过敏反应的担忧。方法:我们分析了来自两个大型欧洲队列的非强制性标签过敏性食物(豌豆、扁豆、豆类、鹰嘴豆、胡芦巴、松仁、向日葵、罂粟、南瓜子、荞麦)过敏反应的频率和严重程度:过敏反应登记处(NORA)和EuroPrevall门诊研究。使用食物过敏严重程度评分(FASS)评估严重程度,并将其与对强制标签过敏食品的反应进行比较。结果在两个队列的589例反应中,葵花籽是最常见的触发因素(n = 126)。在NORA中,松子(1.0%的食物引起的过敏反应)最常见,其次是豌豆和荞麦(各0.7%);EuroPrevall以葵花籽(1.2%)、罂粟籽(0.6%)和扁豆(0.6%)为主。在调整了年龄和性别后,对强制性标签种子和豆类(不包括花生)的反应严重程度没有差异(nFASS中位数:4.39 vs. 4.43, 4.56 vs. 4.49)。而谷物引起的反应(6.47)明显比荞麦(4.77)严重。在诺拉,2015-2022年对葫芦巴和南瓜籽的反应数量比2007-2014年高7.4倍和3.7倍。结论:在两个大型欧洲队列中,非强制性标签致敏性食品被确定为引起严重过敏反应。葵花籽、松子、豌豆和扁豆的频繁涉及,以及葫芦巴和南瓜籽的反应数量也在增加,表明它们的潜在风险。这些致敏食物需要密切监测,并在未来修订过敏原标签时加以考虑。
{"title":"Frequency and Severity of Allergic Reactions to Non-Mandatory Labelled Allergenic Foods-Data From Two Large European Cohorts.","authors":"Sabine Dölle-Bierke,Alejandro Gonzalo-Fernández,Dominique Sabouraud-Leclerc,Laura Barreales-Tolosa,Barbara Ballmer-Weber,Simona Belohlavkova,Maria B Bilò,Ruta Dubakiene,Karin Hartmann,Monika Jedrzejczak-Czechowicz,Thuy-My Le,Lars Lange,Nikolaos G Papadopoulos,Guillaume Pouessel,Isabel Reig,Athanasios Sinaniotis,E N Clare Mills,Margitta Worm,Montserrat Fernández-Rivas","doi":"10.1111/all.70308","DOIUrl":"https://doi.org/10.1111/all.70308","url":null,"abstract":"BACKGROUNDThe consumption of plant-based food has lately largely increased, raising concerns about allergic reactions from ingredients which are currently not subject to mandatory labelling.METHODSWe analysed the frequency and severity of allergic reactions to non-mandatory labelled allergenic foods (pea, lentil, bean, chickpea, fenugreek, pine nut, sunflower-, poppy-, pumpkin seed, buckwheat) from two large European cohorts: The Anaphylaxis Registry (NORA) and EuroPrevall outpatient clinic study. Severity was assessed using the Food Allergy Severity Score (FASS) and compared with reactions to mandatory labelled allergenic foods.RESULTSAmong 589 reactions from both cohorts, sunflower seed was the most frequent trigger (n = 126). In NORA, pine nut (1.0% of food-induced allergic reactions) was most common followed by pea and buckwheat (0.7% each); in EuroPrevall, sunflower seed (1.2%), poppy seed (0.6%) and lentil (0.6%) predominated. After adjusting for age and sex, the severity of reactions to mandatory labelled seeds and legumes (excluding peanut) were not different (nFASS median: 4.39 vs. 4.43 and 4.56 vs. 4.49). Whereas, cereal-induced reactions (6.47) were significantly more severe than buckwheat (4.77). In Nora, the number of reactions to fenugreek and pumpkin seed were 7.4- and 3.7-fold higher in 2015-2022 versus 2007-2014.CONCLUSIONNon-mandatory labelled allergenic foods were identified to cause severe allergic reactions in two large European cohorts. The frequent involvement of sunflower seed, pine nut, pea and lentil, but also rising numbers of reactions to fenugreek and pumpkin seed, indicates their potential risk. These allergenic foods warrant close monitoring and consideration in future allergen labelling revisions.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"92 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2026-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147502160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Allergy
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1